Share Name Share Symbol Market Type Share ISIN Share Description
Neutec Pharma LSE:NTP London Ordinary Share GB0031275315 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p - - - - - - - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown - - - - 0.00

Neutec Pharma Share Discussion Threads

Showing 551 to 572 of 575 messages
Chat Pages: 23  22  21  20  19  18  17  16  15  14  13  12  Older
DateSubjectAuthorDiscuss
28/5/2007
05:32
<img src='http://www.advfn.com/p.php?pid=chartscreenshot&u=NXg%2Bz%2Fpil%2FmzJclGLDCi2cQohMPqixhhR9GAC8GiU7LPVl8DWLg9GA%3D%3D'>
sicilian_kan
20/11/2006
11:28
Interesting comments Off topic, but out of interest due you have any opinions on York Pharma / Alizyme that you would care to share.
bjfanc
18/11/2006
13:02
We should also note that the drug Mycograb is being used in conjunction with (amphotericin B) is falling out of use, being often replaced by Caspofungin these days, which is less toxic to patients. So the Mycograb trials are becoming obsolete.
analyst
18/11/2006
12:50
A lucky escape indeed - NTP shares would have surely plummeted on that news! Although Aurograb may be more important as it is for treatment of MRSA.
bountyhunter
18/11/2006
12:11
Agreed, whoever authorised the deal for Novartis must be well gutted. Interesting article on it at: http://www.pharmalive.com/News/index.cfm?articleid=392874&categoryid=51
sicilian_kan
17/11/2006
17:12
Management sold out at the right time, as this wouldn't have been good for the share price. Close Print 17/11/2006, 2006, 3.03 PM CET Novartis to provide additional clarification to EU regulators on data supporting approval of Mycograb® for serious fungal infections Committee for Medicinal Products for Human Use (CHMP) issues negative opinion on 2005 Mycograb submission by NeuTec, which was acquired by Novartis in mid-2006 CHMP concluded that Mycograb demonstrated efficacy; negative opinion linked to questions about manufacturing and potential implications for product quality and safety Novartis to provide clarification to EU regulators to support Mycograb approval as a novel treatment for critically ill patients Basel, November 17, 2006 - Novartis announced today that it plans to submit additional information to the Committee for Medicinal Products for Human Use (CHMP) in Europe to support the approval of Mycograb®, in development as a treatment for life-threatening fungal infections, after the CHMP issued a negative recommendation. This submission for European Union approval was made in 2005 by the UK biopharmaceuticals company NeuTec Pharma, which Novartis acquired in mid-2006 to expand its portfolio of compounds for hospital-acquired fungal and bacterial infections. The CHMP opinion was not linked to the efficacy of the compound. The Committee concluded that there was insufficient data relating to the manufacturing and characterization of the product to determine the safety of the compound. Novartis is committed to working with the CHMP to determine appropriate next steps. Mycograb is a complex biological product produced through microbial fermentation and is produced by third party manufacturers. Novartis is working closely with these manufacturers and the CHMP to provide further clarification and analyses and is confident of gaining regulatory approval. Mycograb had not been submitted for approval in any other country. Mycograb is a twice-daily intravenous genetically recombinant antibody fragment, or "grab," add-on treatment targeting heat shock protein 90 ("hsp90") developed for treatment of invasive candidiasis. This life-threatening fungal infection, which is due to the Candida species, has a high mortality rate. In clinical trials, the combination of Mycograb plus amphotericin B demonstrated clear superiority over amphotericin B monotherapy, considered the standard of care. Mycograb binds to the fungal hsp90, disabling the fungal defense mechanism and making fungi more susceptible to medicines such as amphotericin B. Mycograb has been granted Orphan Drug status in Europe and the US for use against invasive fungal infections, including invasive candidiasis.
bjfanc
04/7/2006
00:07
game coming 2 an end asmarket not not expecting counter bid shameful
osteo1
30/6/2006
16:10
Can anyone comment on the 4.5 million+ trade? Shown as a buy above.
rrr
29/6/2006
12:23
Indeed , I declined as I would lose little , I am hardly a majority holder. I just thought it odd that they would bother. However it sounds like its all pretty well over anyways.
hazelton
29/6/2006
07:05
decline, you can always accept later........I think?
charlie100
28/6/2006
17:28
My broker has just asked me if I want to accept the offer.
hazelton
28/6/2006
12:51
I too think £10.50 is much too low. EMEA Mycograb approval could come any time, and seems a foregone conclusion, given the data to hand. If Aurograb is also succesful in its latest trials (which IMO seems very likely) the market there must be massive (with attendant high profile press attention for anything to do with MRSA /'hospital superbugs'!). Come on another bidder!! Surely this is worth £20 at least. All IMO. rrr
rrr
27/6/2006
15:34
Over 100/- gone thru at 1054/5 level off sets
charlie100
27/6/2006
15:32
On further checking you may be right, strong bids at 1050p at close
charlie100
27/6/2006
15:04
I believe the IC said the 29th but could be wrong on that. Also, just like to mention that the EMEA review their human drugs this week, abit of a long shot at this point, but you never know.
dimmy2
27/6/2006
12:50
I think they have 21 days to publish an formal offer document, which takes us to tomorrow 28th June, rivals may wait to see this before making a higher offer. That is what I would do anyway?
charlie100
27/6/2006
12:26
Is there a timetable for when it is all finalised ?
hazelton
27/6/2006
08:47
I am convinced that there will be a higher offer, not sure what the level will be.......... However, I notice that there is a good buyer at present who has been paying 1050 and higher and not small amounts of stock, now why would someone be paying such large amounts consistently if there was not going to be a higher offer. In the close auction on friday there were bids for over 50/- shares at 1050p appeared in last few moments of trading.......... any other views..?
charlie100
25/6/2006
18:20
Agreed mw8156, I am really dissapointed with the bid offer and believe it to be too cheap. I had put a higher figure than £30 to £40 on this stock if Aurograb comes up with the goods. I'm hoping it won't succeed but as you say it probably will. Oh well, time will tell.
dimmy2
25/6/2006
12:29
Neutec stock could reach 30 to 40 pounds by 2010 quotes Citywire of Evershed by 2010. This guess is obviously not without risk but in my opinion could be higher with success for any of their other candidates so Im not too keen on the bid offered.I expect the short term city institutions will take the money and run and the Swiss may have picked up a bargain. As for the Directors - they're happy too because the so called long term incentive plan put in place 21` months ago vests large numbers of shares in the event of a takeover making them very wealthy indeed. I was against the plan at the time as they already had plenty of options. The only incentive for a LTIP in addition would be to sell out at the best price in the shortest time scale after two years had elapsed to minimise capital gains tax - a perverse incentive not in the interests of other shareholders who put up their risk capital in the rights issue at the time.
mw8156
18/6/2006
19:58
ft reports juicy counterbid on the way
osteo1
12/6/2006
18:25
OFT Enquiry announced - probably best to sell in the market now.
analyst
Chat Pages: 23  22  21  20  19  18  17  16  15  14  13  12  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20161203 02:25:50